O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study
The DOI matches its Crossref record.
Abstract
Aducanumab (BIIB037) is a human monoclonal antibody selective for aggregated forms of beta-amyloid peptide being investigated as a disease-modifying treatment for AD. This Phase 1b study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of aducanumab in patients with prodromal or mild AD. Patients included in this multicenter, randomized, double-blind, placebo-controlled, multiple-dose study (PRIME; NCT01677572) were aged 50-90 years, had a positive florbetapir (F-AV-45) PET scan, and met clinical criteria for prodromal or mild AD. During the double-blind, placebo-controlled phase, patients received aducanumab or placebo once every 4 weeks for 52 weeks. In a staggered, ascending-dose design, patients were randomized to 1 of 7 treatment arms stratified by ApoE4 status (carrier/non-carrier). Primary endpoint was safety and tolerability. Secondary endpoints included change from baseline to Week 26 in brain beta-amyloid plaque burden measured by PET imaging. Cognition/functioning, including change from baseline on the Clinical Dementia Rating scale, was an exploratory endpoint. Interim analyses included: (1) subjects in all arms who completed the Week 26 visit, and (2) subjects in all arms who completed the Week 54 visit (results for placebo, 1, 3 and 10 mg/kg aducanumab at Week 54 available here, results for 6 mg/kg at Week 54 will be presented). Figure Dose-dependent ARIA was the main safety and tolerability finding. Aducanumab reduced beta-amyloid plaque in patients with prodromal or mild AD. A clinical signal was observed in exploratory analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
“The 3 and 10 mg dose reduced PET amyloid levels at 6 months and more so at 12 months, with the 10 mg dose causing a decline to near the level required for trial entry (Sevigny et al, 2015).”
Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30394-1 · Cited by 313
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189
“Interim results from the 12-month, double-blind, placebo-controlled phase of a phase 1b multiple-dose study of aducanumab in patients with prodromal or mild AD have also reported dose-dependent ARIA as the main safety and tolerability finding and showed dose- and timedependent reductions in Ab plaque with aducanumab […”
Metadata
- Authors
- Sevigny, J., Chiao, P., Williams, L., Chen, T., Ling, Y., O'Gorman, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-07
- Volume
- 11
- Issue
- 7S_Part_6
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2337565256
- Cited by
- 40
- References
- 0
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study. https://app.cochat.ai/papers/10.1016/j.jalz.2015.07.367
- The paper
- Sevigny, J., Chiao, P., Williams, L., Chen, T., Ling, Y., O'Gorman, J., Hock, C., Nitsch, R. M., & Sandrock, A. (2015). O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2015.07.367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.